ArticleBlood2017
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 55 papers.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 101 citations in OpenAlex.
- Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia.Nature cancer · 2024Trial
- Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.Blood advances · 2026Article
- Humanized mouse models in MDS.Cell death & disease · 2025Review
- Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia.Medical oncology (Northwood, London, England) · 2024Review
- Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.American journal of hematology · 2024Review
- Epigenetic Profiling ofCancers · 2023Article
- Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.American journal of hematology · 2023Article
- Srsf2Leukemia · 2022Article
- Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes.Blood cancer discovery · 2022Article
- Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.Leukemia · 2022Article
- Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Increasing Complexity of Molecular Landscapes in Human Hematopoietic Stem and Progenitor Cells during Development and Aging.International journal of molecular sciences · 2022Review
- Review
- Aberrant RNA splicing and therapeutic opportunities in cancers.Cancer science · 2022Review
- A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms.Cancer discovery · 2021Article
- Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment.Blood advances · 2021Article
- Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.Leukemia · 2021Article
- Mouse Models of CMML.International journal of molecular sciences · 2021Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
26 authors at 4 institutions in 1 country.
Akihide YoshimiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Maria E BalasisDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Alexis VedderDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Kira FeldmanDepartment of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
Yan MaDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Hailing ZhangDepartment of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Stanley Chun-Wei LeeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Christopher LetsonDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Sandrine NiyongereDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Sydney X LuHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Markus BallDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Justin TaylorHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Qing ZhangDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Yulong ZhaoDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Salma YoussefHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Young Rock ChungHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Xiao Jing ZhangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Benjamin H DurhamHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Wendy YangDepartment of Pathology and.
Alan F ListDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Mignon L LohDepartment of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
Virginia KlimekLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Michael F BergerDepartment of Pathology and.
Elliot StieglitzDepartment of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
Eric PadronDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Moffitt Cancer Center · USMemorial Sloan Kettering Cancer Center · USUCSF Benioff Children's Hospital · USUniversity of California, San Francisco · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MProject 4: Secondary Cancers Among NF1 Cancer SurvivorsU54CA196519 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI Yunlong Liu · 2015 to 2026
$26.9MGenetic and molecular basis for SRSF2 mutations in myelodysplasiaR01HL128239 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2015 to 2026
$8.0MResearch Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0MNCI NIH HHS P30 CA008748NCI NIH HHS T32 CA128583NCI NIH HHS U54 CA196519NHLBI NIH HHS R01 HL128239
Abstract
Chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) are myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap disorders characterized by monocytosis, myelodysplasia, and a characteristic hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF). Currently, there are no available disease-modifying therapies for CMML, nor are there preclinical models that fully recapitulate the unique features of CMML. Through use of immunocompromised mice with transgenic expression of human GM-CSF, interleukin-3, and stem cell factor in a NOD/SCID-IL2Rγ
Indexed as
AnimalsBridged-Ring CompoundsFemalefms-Like Tyrosine Kinase 3HeterograftsHumansJanus Kinase 2Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myelomonocytic, JuvenileMaleMiceMice, Inbred NODMice, SCIDMyelodysplastic SyndromesNeoplasm ProteinsNeoplasm Transplantation11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeneBridged-Ring CompoundsFLT3 protein, humanfms-Like Tyrosine Kinase 3JAK2 protein, humanJanus Kinase 2Neoplasm ProteinsPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.